AU2002220376B2 - Method of creating biological and biosynthetic material for implantation - Google Patents

Description

WO 02/49687 PCT/AU01/01619 -1 METHOD OF CREATING BIOLOGICAL AND BIOSYNTHETIC MATERIAL FOR IMPLANTATION Background to the Invention Field of the Invention The present invention relates to a method of creating biological and biosynthetic material suitable for implantation to replace or augment damaged, diseased or absent tissues, structures or organs, of particular but by no means exclusive application in the treatment of autogenic, allogenic or xenogenic material of mammalian origin, to maintain a microarchitectural organization and inhibit in vivo calcification, tissue ingrowth and transmural angiogenesis. In one embodiment, as may be determined by the end use, transplanted living cells can be attached and retained under in vivo conditions.

Description of Related Art Tissue stabilization and fixation using, for example, glutaraldehyde to impart strength, neutralize antigenic sites and sterilize biosynthetic and biological tissue for human implantation has been described previously.

US Patents Nos. 4,319,363, 4,466,139 and 4,681,588 (Ketharanathan) disclose the processing of biosynthetic and biological material at a constant concentration of glutaraldehyde and at a constant pH in a static fluid environment in order to impart strength and durability, neutralize antigenic sites and sterilize the material.

US Patent No. 3,966,401 (Hancock and Fogarty) describes a method of pressurizing tissues, such as those of a heart valve, with a tanning fluid such as glutaraldehyde, to within the physiological range, and releasing the pressure such that natural tissue retains flexibility. On the other hand US Patent No. 4,798,611 (Freeman) discloses a method of sterilizing, imparting compliance and reducing antigenecity by gamma radiating xenogenic material at a SUBSTITUTE SHEET (RULE 26) RO/AU WO 02/49687 PCT/AU01/01619 2 level of 2 to 8 megarads following treatment with a cross linking agent, for example, glutaraldehyde.

In vivo calcification has been reported in implanted glutaraldehyde treated biological tissue prostheses, particularly heart valve prostheses. In vivo microcalcification was demonstrated in the wall of the material of US Patent No. 4,466,139 when used as a vascular conduit in dogs, though the calcification did not cause the material to fail. Storage in 50% alcohol prior to implantation reduced but did not eliminate the degree of calcification. A number of methods have been instituted in an effort to reduce or eliminate calcification. US Patent No. 4,648,881 (Carpentier et al.) describes a method of inhibiting calcification in biological tissue by the use of phosphate deficient solution, and US Patent No. 5,931,969 (Carpentier et al.) discloses treating at least partially fixed tissue in a heated treatment solution and inducing tissue/solution movement for between 15 and 60 days. In US Patent No. 5,843,181 (Jaffe and Hancock) a method is disclosed whereby biological tissue is made substantially acellular by exposure to at least one buffered solution with a pH in the range of 5 to 8 prior to fixation. US Patent No. 5,746,775 (Levy and Hirsch) discloses the inhibiting of in vivo calcification by subjecting tissue to an aqueous solution of 60 to 80% lower aliphatic alcohol containing an anti-calcification agent for at least minutes following glutaraldehyde pre-treatment.

Various methods of pre-treatment of substrates with extracellular matrix proteins to emulate a protein surface, in an effort to promote growth, attachment and retention of living transplanted cells onto the surface of synthetic materials, have been documented. For example, coating polyester graft material with human plasma and fibrin gel for the attachment of endothelial cells on synthetic vascular graft surfaces to provide at least 50% confluence SUBSTITUTE SHEET (RULE 26) ROIAU PCT/AU01/01619 Received 04 July 2002 3is disclosed in US Patent No. 4,820,626 (Williams and Jarrell). US Patent No. 5,632,778 (Goldstein) describes a method of killing native cells in interstitial collagen, removing potentially immunogenically active soluble molecules and subsequently treating the acellular tissue with extracellular substances and transplanting allogenic or autologous cells prior to implantation of the graft material.

Considerable attention has been paid to the appropriate pore size of synthetic materials for implantation in order to promote healing or biolisation via tissue ingrowth and more recently for transmural angiogenisis to promote endothelialisation. An unwanted aspect is the uncontrolled nature of tissue ingrowth particularly in vascular conduits of 6 mm internal diameter and less which causes lumenal narrowing, thrombosis and occlusion with subsequent graft failure.

Summary of the Invention The present invention provides a method of creating an implantation material from mammalian autogenic, allogenic or xenogenic tissue, said tissue comprising between 20% and and preferably 40% collagen by weight, said method involving: treating said tissue with a cross linking agent for a time period of between 30 minutes and 6 hours, including varying said cross linking agent concentration from an initial concentration of from 0% to 0.25% weight/volume to a final concentration of from 0.5% to weight/volume over said time period and varying said cross linking agent pH from an initial pH of from 1 to 3 to a final pH of from 5 to 8 over said time period.

Preferably the method includes treating said tissue with said cross linking agent for a time period of approximately hours.

AMENDED SHEET

IPEAAU

4 SPreferably said method includes progressively increasing said cross linking agent concentration and said pH over S said time period.

Preferably said initial concentration is approximately 0%.

Preferably said final concentration is approximately weight/volume.

Preferably said initial pH is approximately SPreferably said final pH is approximately 7.4.

The tissue may be autogenic, allogenic or xenogenic material of, for example, human, ovine, bovine and porcine origin. The tissue may be tissue engineered biological material or material tissue engineered on a durable or degradable scaffold in a surrogate animal or by tissue culture systems in the laboratory. The tissue may be naturally occurring biological material such as ureters, pleura and blood vessels. The tissue may be of any configuration including tubular, sheet-like or three dimensional.

Preferably the cross linking agent is glutaraldehyde.

The material is preferably treated in a circulating fluid bath or a rotating drum. In a circulating bath, tubular material may be attached to a flow system such that the fluid flows through the lumen of each tube at a rate of 200 to 400 mL per minute and preferably 300 mL per.minute.

Preferably the method additionally includes, after said time period, treating said tissue with a cross linking agent (preferably a fresh solution thereof) at a concentration of from 0.5% to 5% (preferably weight/volume and a pH of from 5 to 8 (preferably at a temperature of from 20 0 C to 27 0 C (preferably 25 0 for a further time period of from 1 hour to 5 days (preferably 48 WO 02/49687 PCT/AU01/01619 5 hours) Preferably the tissue and cross linking agent solution is maintained at a temperature of from 200 C to 270 C but preferably approximately 25* C.

The configuration of said tissue is preferably maintained during treating by means of a compressible template to which the tissue is, preferably, either untethered, or tethered at only one end to allow movement of the material on said template.

Thus, microarchitectural alignment of the tissue is maintained without damaging the tissue.

Preferably said method includes sterilizing said tissue after said tissue has been cross linked, preferably either chemically, or by gamma irradiation in, preferably, 15 to kilograys (kgys) and preferably 25 kgys.

Optionally the method includes immersing the tissue prior to sterilization in 2% weight/volume hydrogen peroxide for between 30 minutes and 1.5 hours but preferably approximately 1 hour.

Optionally the method includes incubating the tissue in glycine 5% weight/volume prior to gamma irradiation sterilization, for 2 to 24 hours and preferably for 12 hours.

Preferably the method includes storing said material in volume/volume ethyl alcohol ethanol) for a minimum of three weeks and preferably three months prior to implantation.

Thus, the treating of the tissue in this manner has been found to provide a material with an intact SUBSTITUTE SHEET (RULE 26) RO/AU WO 02/49687 PCT/AU01/01619 6 microarchitecture and cellular lining which inhibits in vivo calcification, tissue ingrowth and transmural angiogenesis, and provides a microenvironment for the adhesion of transplanted living cells. Additionally, haemocompatibility, compliance and flexibility can be varied according to the desired end use by varying the process within the functional range.

The present invention also provides an implantation material created by the method described above.

Brief Description of Figures In order that the present invention may be more clearly ascertained, a preferred embodiment will now be described, by way of example, by reference to the accompanying figures, in which: Figure 1 is a haematoxylin and eosin stain (H E) photomicrograph of a bovine ureter processed according to the method of a preferred embodiment of the present invention and implanted for 127 days as a vascular substitute in the canine model; Figure 2 is an H E photomicrograph of a bovine ureter treated according to the method of US Patent No.

4,466,139 and implanted for 90 days as a vascular substitute in the canine model; and Figure 3 is a photomicrograph of a monolayer anti CD31 labelled human saphenous vein endothelial cells attached to the flow surface of a bovine ureter that had been treated according to the method of the preferred embodiment.

Detailed Description The current invention is based on the surprising discovery that by subjecting autogenic, allogenic and xenogenic tissue engineered biosynthetic and biological material or naturally occurring biological material to a gradual increase in the concentration of a cross linking agent such SUBSTITUTE SHEET (RULE 26) RO/AU WO 02/49687 PCT/AU01/01619 7 as glutaraldehyde and a gradual change in pH from acid towards alkaline, in combination with a dynamic fluid environment, preferably, a storage period of at least three weeks in 50% volume/volume ethanol after processing would provide a non-porous biomatrix with an intact microarchitecture which is impervious to tissue ingrowth and angiogenisis, would inhibit in vivo calcification, and would be suitable for the attachment and retention of transplanted living cells. Additionally, flexibility and compliance could be controlled by the gradual penetration of cross linking agent into the biosynthetic or biological material which is untethered or only tethered at one end to a compressible template during processing.

The resultant material, which has a durable biological microarchitecture and a surface that is lined with stabilized cells, for example fibroblasts on tissue engineered material and urothelium lining mammalian ureters, has an affinity for transplanted living cells and an ability to retain them under required biological conditions. Transplanted living cells are more likely to interact with the naturally occurring extracellular matrix (ECM) proteins of these cellular linings via many cellular binding sites, each of which may have more than one protein ligand, than to single ECM or derivatives of ECM which are used to coat polyester and polytetrafluroethylene material to aid in the adhesion of endothelial cells. It is postulated that the ECM binding sites are still recognized and available for cell attachment by transplanted cells even though the biomatrix has been cross linked with glutaraldehyde. In the case of biosynthetic material the tissue engineered biological interface is presented to the living environment, the synthetic component being an endoskeletal structure only and never in contact with living structures.

The characteristics of the material can be varied for SUBSTITUTE SHEET (RULE 26) ROIAU WO 02/49687 PCT/AU01/01619 8 specific applications or for specific materials by the variation of the parameters of the time, percentage glutaraldehyde and pH within the functional range. For example in the case of autogenic tissue created in the laboratory, glutaraldehyde is utilized to arrest tissue proliferation at the optimal level, whereas in non autogenic tissue glutaraldehyde renders the material nonimmunogenic. The degree of flexibility, compliance and durability can be varied by degree and intensity of dynamic processes.

Thus, in a method of creating implantation material by treating autogenic, allogenic and xenogenic tissue (such as tissue engineered biosynthetic and biological material and naturally occurring biological tissue in tubular, flat sheet and three dimensional configurations for surgical implantation) according to a preferred embodiment of the present invention, excess tissue is first removed from the exterior of the tissue.

The tissue is then tethered to a compressible template such that movement of the tissue on the template is not restricted. In the case of tubular tissue, the tissue is left untethered to a compressible mandrel The mounted tissue is placed into a rotating drum at between 10 and 20 rpm preferably 12 rpm, or into a circulating bath at approximately 250 C. If placed in a circulating bath, the tubular tissue may be attached to a flow system such that fluid flows through the lumen at approximately 300 mL per minute.

A cross linking agent in the form of glutaraldehyde is added to the drum or bath, the concentration of which is gradually increased from 0% up to a predetermined maximum of 2.5% weight/volume; the pH of the solution is gradually increased from 1.5 to 7.4 over a period of 2.5 hours.

SUBSTITUTE SHEET (RULE 26) ROIAU WO 02/49687 PCT/AU01/01619 9 Once the predetermined final concentration and pH of glutaraldehyde solution has been reached, the tissue is removed from the rotating drum and placed in a circulating bath of fresh solution of glutaraldehyde which is then maintained at a concentration of 2.5% weight/volume and a pH of 7.4, at a temperature of 25 0 C. Alternatively, if the tissue is already in the circulating bath the solution is renewed as above and if attached to the flow system, the flow system is removed and solution replaced as above. The tissue remains in the circulating bath for approximately 48 hours. The tissue is then immersed in 2% weight/volume hydrogen peroxide for one hour.

The tissue (or, now, implantation material) is then sterilized chemically in a 1% weight/volume solution of glutaraldehyde and 50% volume/volume ethanol for not less than 18 hours. Alternatively it can be sterilized in gamma radiation at 15 to 30 kgys but preferably 25 kgys.

Optionally the tissue is incubated in glycine weight/volume for 2 to 24 hours, but preferably 12 hours, prior to sterilization.

Finally, the tissue is stored in 50% volume/volume ethanol for a minimum of three weeks and preferably three months.

Example 1 The method of treating tissue according to this embodiment was applied to bovine ureters for use as vascular prostheses as follows.

Bovine ureters were collected under hygienic conditions and transported to the laboratory at 40 C. Physiological saline was pumped via the pelvic end of the ureter. The distal or bladder end was temporarily occluded and the pressure of the saline within the lumen was increased to SUBSTITUTE SHEET (RULE 26) RO/AU WO 02/49687 PCT/AU01/01619 10 115 nun Hg. The diameter of the ureter at the mid point was recorded. A compressible silicone mandrel slightly narrower in diameter than the ureter and mounted on a blunt nosed steel introducer was inserted atraumatically into the pressure filled ureter. The metal introducer was removed.

Excess tissue was removed from the exterior of the ureter.

The ureter was then tethered to the silicone at one end, allowing some movement along the silicone. The mounted ureter was placed into a rotating drum at 12 rpm at a temperature of 210 C. The concentration of glutaraldehyde was gradually increased from 0 to a predetermined concentration of 2.5% weight/volume and the pH of solution increased from 1.5 to 5.9 by the addition of phosphate buffers over a period of 3 hours. Once the predetermined concentration and pH of glutaraldehyde solution were reached, the ureter was removed from the rotating drum and placed into a circulating bath of 2.5% weight/volume glutaraldehyde at 7.4 pH for 24 hours.

The material was removed from the glutaraldehyde, rinsed briefly in buffered saline and placed in 50% volume/volume ethanol. The compressible mandrel was removed and the integrity of the material was ascertained by pressure testing.

The material was chemically sterilized by soaking in a solution of 50% volume/volume ethanol in 1% glutaraldehyde for not less than 18 hours; the material was rinsed of sterilization solution with 50% volume/volume ethanol and stored in 50% volume/volume ethanol for a minimum of three weeks.

Example 2 In vivo inhibition of calcification was assessed in greyhound dogs as follows.

Grafts of 6 mm internal diameter and not less than 10 cm in SUBSTITUTE SHEET (RULE 26) RO/AU WO 02/49687 PCT/AU01/01619 11 length prepared from bovine ureters according to this embodiment were implanted into the aorto-iliac position with the distal aorta to the proximal anastomosis ligated.

Grafts of 4 nun internal diameter and not less than 6 cm in length were implanted as femoral interposition grafts.

No anti-coagulation or antiplatelet therapy was used.

Periodic angiograms were taken at predetermined intervals to verify patency and detect aneurysms, dilatation or stenoses. The animals were sacrificed at predetermined intervals, or at graft closure or animal distress.

Finally, macro- and microscopic examination of the explants were performed.

When patency, mural integrity and luminal integrity of implanted material processed by the current invention were compared with that of US Patent No. 4,466,139 neither was compromised. However, when examined microscopically, there was no calcification in 13 prostheses explanted at 1 to 18 months processed by the method of this embodiment. Figure 1 is a haematoxylin and eosin stain (H E) photomicrograph of a bovine ureter processed according to this embodiment and implanted for 127 days as a vascular substitute in the canine model. The graft wall is clear of microcalcification at explant. In the view shown, the flow surface FS is to the right.

By contrast, at the same time period 11 of 25 prostheses 44%) processed according to the method of US Patent No 4,466,139 had areas of micro-calcification in the wall, primarily at the anastomotic sites. Figure 2 is an H E photomicrograph of a bovine ureter processed as per US Patent No. 4,466,139 and implanted for 90 days as a vascular substitute in the canine model. At explant, areas of micro-calcification (Ca) were demonstrated in the wall SUBSTITUTE SHEET (RULE 26) RO/AU WO 02/49687 PCT/AU01/01619 12 at the distal anastomosis. The graft was patent at explant. In the view shown, the flow surface (FS) is to the right.

Example 3 The attachment and adherence of human saphenous vein endothelial cells transplanted onto the surface of the processed bovine ureter were evaluated as follows.

Human saphenous vein endothelial cells were isolated, harvested and seeded using published or modified techniques. Human saphenous vein endothelial cells were isolated from inverted varicosed human saphenous vein segments obtained from the operating room and transported to the laboratory in chilled Hanks Balanced Salt Solution (HBSS, Sigma Australia) containing ampicillin (lOO1g/mL), gentamycin (50 gg/mL), amphotericin B (2.5 gg/mL), L-glutamine (2.5 mM) and sodium bicarbonate and stored at 40 C. The ends of the veins were ligated with surgical silk. A modified enzymatic harvesting technique was utilized whereby the veins were immersed in 10 mL of 2 mg/mL collagenase (Worthington type IV, Sigma) for minutes at 370 C then vortexed on an automatic speed for 1 minute at 10 second intervals. The collected cell suspension was centrifuged at 800 g for 5 min at 40 C and the resultant cell pellet re-suspended in 7.5 mL of M199 (Sigma Australia) containing heat inactivated foetal bovine or calf serum (FCS, CSL Australia), heparin (50 pg/mL, Sigma Australia) and endothelial cell supplement (Sigma Australia). Cells were then plated onto gelatin coated diameter Petri dishes and incubated at 370 C in a CO2, 95% air humidified incubator (NuAire USA). Cells were grown to confluence and passaged 3 times.

Endothelial cells were dissociated from the tissue culture plates using trypsin containing 0.25% Trypsin/0.2% EDTA (Sigma Australia) for 1 min. The activity of the trypsin SUBSTITUTE SHEET (RULE 26) RO/AU WO 02/49687 PCT/AU01/01619 13 was inactivated with 20% FCS and M199 and the cell suspension was centrifuged at 40 C, 800 g for 5 minutes.

The cell pellet was re-suspended in culture medium to a cell concentration of 1x10 6 cells/mL.

Conduits 4 mm in internal diameter and not less than 10 cm long, were filled with the cell solution and rolled (16 rotation/h) for one hour in 370 C incubator. After seeding, the conduits were incubated at 370 C under 5% CO 2 Conduit samples (1 cm) were taken after 0, 24, 48 and 72 h of incubation in order to assess percentage cell cover and cell density.

Conduits seeded with human saphenous vein endothelial cells had greater than 50% confluent cover after 72 hours incubation. The conduits were subjected to in vitro flow of media at 480 mL/min and a shear stress of 11.4 dynes/cm 2 for one hour delivered by an in vitro flow system consisting of a blood monitor pump (Gambro BMM10-1/3) to three seeded conduits attached to the outflow line in parallel.

Pre and post flow endothelial cell cover was determined following labelling of cells with anti CD31 antibody (PECAM). Labelled cells were detected with an alkaline phosphatase labelled streptavivdin/biotin system with a bromo-4-chloro-3-indolylphosphate-nitroblue tetrazolium (BCIP/NBT) chromagen (Dako Australia).

Results Confluent monolayers of endothelial cells were firmly adherent to the biomatrix surface consisting of urothelial cells, and remained adherent under in vitro shear stresses of 11.4 dynes/cm 2 Figure 3 is a photomicrograph of anti CD31 labelled cells detected with an alkaline phosphatase labelled stretavidin/biotin system with a BCIP/NBT chromagen. Figure 3 shows a monolayer of human saphenous SUBSTITUTE SHEET (RULE 26) RO/AU 14 vein endothelial cells (EC) attached to the flow surface of a bovine ureter, processed according to this embodiment, after one hour of in vitro shear stresses of 11.4 dynes/cm 2 In this figure, the lamina propria is labelled LP, and the urothelium is labelled URO.

Thus, the method of this embodiment can be applied to autogenic, allogenic and xenogenic tissue to create implantation material for humans or animals to replace or augment damaged, diseased or absent tissues, structures or organs. The method can be adjusted to impart the required characteristics to biological or biosynthetic tissue for implants for specific applications. The resultant material could be implanted into the cardiovascular environment for example as a small vessel coronary or peripheral bypass graft, an artificial tissue heart valve or a stent biobarrier to prevent tissue ingrowth and hence in-stent stenosis. The non-porous and tissue impervious nature of the processed material inhibits the ingrowth of tissue and angiogenesis through the wall, one of the major causes of failure in small diameter synthetic bypass grafts. The material could also be implanted into the noncardiovascular environment as for example an artificial skin, hernia repair patch or artificial ligament. Function of the material can be further enhanced by the addition of living cells prior to implantation. For example the addition of endothelial cells onto the flow surface of the small vessel replacement would provide anticoagulant function to prevent the blood clotting.

Modifications may be made to the invention as will be apparent to a person skilled in the art. These and other modifications may be made without parting from the ambit of the current invention, the nature which may be ascertained from the foregoing description and the figures.

Furthermore, any reference herein to prior art is not intended to imply that such prior art forms or formed a part of the common general knowledge.

Claims (21)

1. A method of creating an implantation material from mammalian autogenic, allogenic or xenogenic tissue, said tissue comprising between 20% and 80% collagen by weight, said method involving: treating said tissue with a cross linking agent for a time period of between 30 minutes and 6 hours, including varying said cross linking agent concentration from an initial concentration of from 0% to 0.25% weight/volume to a final concentration of from 0.5% to weight/volume over said time period and varying said cross linking agent pH from an initial pH of from 1 to 3 to a final pH of from 5 to 8 over said time period.

2. A method as claimed in claim i, wherein said tissue comprises approximately 40% collagen by weight.

3. A method as claimed in either claim 1 or 2, including progressively increasing said cross linking agent concentration and said pH over said time period.

4. A method as claimed in any one of the preceding claims, wherein said initial concentration is approximately 0% and said final concentration is approximately weight/volume.

A method as claimed in any one of the preceding claims, wherein said initial pH is approximately 1.5 and said final pH is approximately 7.4.

6. A method as claimed in any one of the preceding claims, wherein said tissue is of human, ovine, bovine and porcine origin.

7. A method as claimed in any one of the preceding claims, wherein said tissue is tissue engineered biological material, material tissue engineered on a durable or 16 degradable scaffold in a surrogate animal, material tissue engineered by tissue culture systems in a laboratory, or naturally occurring biological material.

8. A method as claimed in any one of the preceding claims, wherein said cross linking agent is glutaraldehyde.

9. A method as claimed in any one of the preceding claims, wherein said material is tubular and said method includes: treating said material in a circulating fluid bath or a rotating drum; and attaching said material to a flow system such that fluid flows through the lumen of said material at a rate of 200 to 400 mL per minute.

A method as claimed in any one of the preceding claims, including, after said time period, treating said tissue with a cross linking agent at a concentration of from 0.5% to 5% weight/volume and a pH of from 5 to 8, at a temperature of from 20 0 C to 27 0 C, for a further time period of from 1 hour to 5 days.

11. A method as claimed in either claim 17 or 18, including, after said time period, treating said tissue with a cross linking agent at a pH of approximately 7.4 and at a temperature of approximately 25 0 C.

12. A method as claimed in any one of the preceding claims, including maintaining said tissue and cross linking agent solution at a temperature of from 20 0 C to 27 0 C.

13. A method as claimed in any one of the preceding claims, including maintaining the configuration of said tissue during treating by means of a compressible template.

14. A method as claimed in claim 13, wherein said tissue is either untethered, or tethered at only one end to allow movement of said material on said template. O 17- c

15. A method as claimed in any one of the preceding Sclaims, including sterilizing said tissue after said tissue has been cross linked.

16. A method as claimed in claim 15, including immersing said tissue prior to sterilization in approximately 2% \O weight/volume hydrogen peroxide for between 30 minutes and hours. C( 10

17. A method as claimed in either claim 15 or 16, including sterilizing said tissue chemically, or sterilizing said tissue by means of gamma irradiation in to 30 kilograys.

18. A method as claimed in any one of claims 1 to 16, including incubating said tissue in glycine weight/volume for 2 to 24 hours, and subsequently sterilizing said tissue by means of gamma irradiation in to 30 kilograys.

19. A method as claimed in any one of the preceding claims, including storing said material in volume/volume ethanol for a minimum of three weeks prior to implantation.

An implantation material created by means of the method of any one of claims 1 to 19.

21. A method of creating an implantation material substantially as hereinbefore described with reference to the accompanying examples. Dated this 7th day of June 2006 KRYOCOR LIMITED By their Patent Attorneys GRIFFITH HACK Fellows Institute of Patent and Trade Mark Attorneys of Australia